Premium
Intrathecal arabinosyl cytosine in meningeal leukemia
Author(s) -
Wang Jaw J.,
Pratt Charles B.
Publication year - 1970
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197003)25:3<531::aid-cncr2820250306>3.0.co;2-g
Subject(s) - medicine , intrathecal , leukemia , cytosine , meningeal carcinomatosis , surgery , pathology , immunology , cerebrospinal fluid , dna , genetics , biology
Intrathecal arabinosyl cytosine was administered on a twice weekly schedule, in a dosage range of 5 to 70 mg per square meter of body surface area, to 13 children with meningeal leukemia. Eleven children with acute lymphocytic leukemia had been previously treated with intrathecal methotrexate, and 7 had received cranial or craniospinal radiotherapy. Seven of these 11 children responded with relief of symptoms and reduction of cerebrospinal fluid (CSF) cell count to less than 10 mononuclear cells per mm 3 of CSF and less than 2 leukemic cells on one smear of CSF sediment. The median duration of response was 28 days. Vomiting occurred in 5 children after treatment, headache in 2, and fever in one. Neither leukopenia nor other systemic toxicity was observed. It is concluded that intrathecal arabinosyl cytosine has therapeutic activity against meningeal leukemia.